Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity

J Hypertens. 2004 Oct;22(10):1977-82. doi: 10.1097/00004872-200410000-00021.

Abstract

Objective: Based on results of in vitro studies, it has been hypothesized that blockade of the renin-angiotensin system (RAS) promotes the recruitment and differentiation of pre-adipocytes and that increased formation of small insulin-sensitive adipocytes counteracts ectopic deposition of lipids, thereby improving insulin sensitivity. We investigated the effect of RAS blockade on insulin sensitivity, adipocyte size, and intramuscular lipid content in fructose-fed rats (FFR) as a model of insulin-resistant hypertension.

Design and methods: Six-week-old male Sprague-Dawley rats were divided into two groups: those fed a standard chow (control) and those fed a fructose-rich chow for 6 weeks. FFR were treated with a vehicle or with 1 mg/kg per day of temocapril, an angiotensin-converting enzyme inhibitor, or 0.1 mg/kg per day of olmesartan, an angiotensin II type 1 receptor blocker, for the last 2 weeks. Insulin sensitivity (M value: mg/kg per min) was estimated by the euglycemic hyperinsulinemic glucose clamp method. Sizes of adipocytes derived from epididymal fat and triglyceride content in the soleus muscle were determined.

Results: FFR had lower M value, higher blood pressure, larger adipocyte size, higher ratio of epididymal fat pads over body weight (%fat pads), and higher intramuscular triglyceride than did the control rats. Both temocapril and olmesartan significantly improved the M value and decreased blood pressure and adipocyte size without change in %fat pads in FFR. Adipocyte size was negatively correlated with the M value. Treatment for 2 weeks decreased, but not significantly, intramuscular triglyceride.

Conclusions: RAS blockade decreases adipocyte size without change in epididymal %fat pads accompanied by improvement in insulin sensitivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / pathology*
  • Administration, Oral
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Cell Size / drug effects
  • Epididymis
  • Fructose / administration & dosage
  • Hypertension / chemically induced
  • Hypertension / metabolism
  • Hypertension / physiopathology*
  • Imidazoles / pharmacology*
  • Insulin Resistance*
  • Male
  • Muscle, Skeletal / metabolism
  • Olmesartan Medoxomil
  • Rats
  • Rats, Sprague-Dawley
  • Renin-Angiotensin System / drug effects*
  • Tetrazoles / pharmacology*
  • Thiazepines / pharmacology*
  • Triglycerides / metabolism

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Imidazoles
  • Tetrazoles
  • Thiazepines
  • Triglycerides
  • Fructose
  • Olmesartan Medoxomil
  • temocapril hydrochloride